Amicus receives growth capital from HBM Healthcare Investments

IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


Amicus receives growth capital from HBM Healthcare Investments

Sponsored by

21WalderWyss.png

PRESS RELEASE, Zurich, 6 July, 2017

HBM Healthcare Investments invested EUR 20 million into the privately held and Switzerland based Amicus SA. The financing will allow Amicus to accelerate the growth of its pharmaceutical business in Central and Eastern Europe (CEE).

Walder Wyss acted as advisor in all legal aspects of the transaction. The team was led by Markus Vischer (Partner, Corporate/M&A) and further included Christian Hagen (Associate, Corporate/M&A), Samuel Lieberherr (Associate, Corporate/M&A), Thomas Meister (Partner, Tax) and Christoph Stutz (Associate, Employment).

Gift this article